Ballew Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Ballew Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-300	Closed	-$1K	–	151
2018 Q3	$1K	Buy	+300	New	+$940	﹤0.01%	424

Other funds holding CPRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ballew Advisors's CPRX Position: Q4 2018 in Review

Ballew Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 300 shares — an estimated $1K sold.

Ballew Advisors first reported a position in CPRX in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

Ballew Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 300 Catalyst Pharmaceutical shares in Q4 2018, an estimated $1K.
Ballew Advisors first reported a position in Catalyst Pharmaceutical in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Catalyst Pharmaceutical position peaked at $1K in Q3 2018.
86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.